Statins as inhibitors of voltage-gated potassium channels Kv1.3 in cancer cells.
Cancer cell apoptosis
Cancer cell proliferation
Jurkat T cell
Kv1.3 channel
Patch-clamp
Statin
Journal
Journal of molecular structure
ISSN: 0022-2860
Titre abrégé: J Mol Struct
Pays: Netherlands
ID NLM: 0141747
Informations de publication
Date de publication:
15 Apr 2021
15 Apr 2021
Historique:
received:
01
10
2020
revised:
07
12
2020
accepted:
29
12
2020
pubmed:
14
1
2021
medline:
14
1
2021
entrez:
13
1
2021
Statut:
ppublish
Résumé
Voltage-gated potassium channels are integral membrane proteins selectively permeable for potassium ions and activated upon change of membrane potential. Voltage-gated potassium channels of the Kv1.3 type were discovered both in plasma membrane and in inner mitochondrial membrane (mito Kv1.3 channels). For some time Kv1.3 channels located both in plasma membrane and in mitochondria are considered as a potentially new molecular target in several pathologies including some cancer disorders. Lipophilic nontoxic organic inhibitors of Kv1.3 channels may potentially find a clinical application to support therapy of some cancer diseases such as breast, pancreas and lung cancer, melanoma or chronic lymphocytic leukaemia (B-CLL). Inhibition of T lymphocyte Kv1.3 channels may be also important in treatment of chronic and acute respiratory diseases including severe pulmonary complication in corona virus disease Covid 19, however further studies are needed to confirm this supposition. Statins are small-molecule organic compounds, which are lipophilic and are widely used in treatment of hypercholesterolemia and atherosclerosis. Electrophysiological studies performed in our laboratory showed that statins: pravastatin, mevastatin and simvastatin are effective inhibitors of Kv1.3 channels in cancer cells of human T cell line Jurkat. We showed that application of the statins in the concentration range from 1.5 μM to 50 μM inhibited the channels in a concentration-dependent manner. The inhibitory effect was the most potent in case of simvastatin and the least potent in case of pravastatin. The inhibition was partially irreversible in case of simvastatin and fully reversible in case of pravastatin and mevastatin. It was accompanied by a significant acceleration of the current inactivation rate without any significant change of the activation rate. Mechanism of the inhibition is probably complex, including a direct interaction with the channel protein and perturbation of lipid bilayer structure, leading to stabilization of the inactivated state of the channels.
Identifiants
pubmed: 33437096
doi: 10.1016/j.molstruc.2021.129905
pii: S0022-2860(21)00036-3
pmc: PMC7789826
doi:
Types de publication
Journal Article
Langues
eng
Pagination
129905Informations de copyright
© 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
The authors: Andrzej Teisseyre, Anna Uryga and Krystyna Michalak, declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Biomed Pharmacother. 2019 Jan;109:1511-1522
pubmed: 30551403
Immunol Rev. 2009 Sep;231(1):59-87
pubmed: 19754890
Front Pharmacol. 2020 Feb 21;11:101
pubmed: 32153409
Inflamm Res. 2015 Oct;64(10):753-65
pubmed: 26206235
Curr Pharm Des. 2006;12(18):2199-220
pubmed: 16787250
Cancer Detect Prev. 2006;30(4):375-85
pubmed: 16971052
J Gen Physiol. 1992 Jan;99(1):63-84
pubmed: 1371308
Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1251-9
pubmed: 20114030
J Gen Physiol. 1966 Nov;50(2):491-503
pubmed: 11526842
Sci Rep. 2015 Nov 30;5:17381
pubmed: 26616555
Front Physiol. 2013 Oct 10;4:283
pubmed: 24133455
J Physiol Sci. 2012 May;62(3):267-74
pubmed: 22328488
Front Oncol. 2019 Sep 24;9:933
pubmed: 31612103
Biochem Pharmacol. 2002 Aug 15;64(4):595-607
pubmed: 12167478
Drug Discov Ther. 2020 Jul 15;14(3):143-144
pubmed: 32581194
Expert Opin Ther Targets. 2016;20(5):577-91
pubmed: 26634786
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30823672
Pharmacol Rev. 2012 Jan;64(1):102-46
pubmed: 22106090
Mol Pharmacol. 1996 Dec;50(6):1625-34
pubmed: 8967986
Pflugers Arch. 1981 Aug;391(2):85-100
pubmed: 6270629
Med Hypotheses. 2020 Nov;144:110001
pubmed: 32758867
Pharmacol Rep. 2014 Aug;66(4):712-7
pubmed: 24948077
Adv Clin Exp Med. 2015 May-Jun;24(3):517-24
pubmed: 26467143
J Gen Physiol. 1993 Oct;102(4):601-30
pubmed: 7505804
Am J Physiol Cell Physiol. 2009 Dec;297(6):C1544-53
pubmed: 19794143
Pharmacol Rev. 2005 Dec;57(4):473-508
pubmed: 16382104
J Biol Chem. 1992 Apr 25;267(12):8650-7
pubmed: 1373731